Nexalin technology announces planned clinical trial utilizing gen-3 halo headset in partnership with uc san diego & san diego va

Gen-3 halo headset designed to offer convenient at-home treatment through virtual clinic model study to build on positive results from previous clinical trial treating veterans with mild traumatic brain injury (mtbi) houston, tx, oct. 22, 2024 (globe newswire) -- nexalin technology, inc. (nasdaq: nxl; nxliw) (the “company” or “nexalin”) today announced plans to commence a new clinical trial in collaboration with the university of california, san diego (ucsd). dr ming xiong huang, the ucsd principal investigator, will utilize his affiliation with the san diego va to recruit some of the patients for the study who have been victims of traumatic brain injury (tbi).
NXL Ratings Summary
NXL Quant Ranking